Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLM NASDAQ:ATHE NASDAQ:BFRI NASDAQ:HYPD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMApollomics$19.56$15.59$3.66▼$42.12$43.03M1.4416,848 shs14,795 shsATHEAlterity Therapeutics$5.36$4.52$4.14▼$350.00$47.54M0.25106,105 shs19,500 shsBFRIBiofrontera$1.01$0.97$0.55▼$1.19$12.93M0.81257,774 shs394,399 shsHYPDHyperion DeFi$3.11$3.47$2.49▼$16.35$47.15M2.49697,632 shs425,842 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMApollomics0.00%-5.96%+37.26%+33.74%+200.69%ATHEAlterity Therapeutics0.00%+9.50%+37.44%+51.16%+32.84%BFRIBiofrontera0.00%+4.02%+8.02%+2.02%+43.06%HYPDHyperion DeFi0.00%+2.81%+4.01%-5.76%-80.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMApollomics$19.56$15.59$3.66▼$42.12$43.03M1.4416,848 shs14,795 shsATHEAlterity Therapeutics$5.36$4.52$4.14▼$350.00$47.54M0.25106,105 shs19,500 shsBFRIBiofrontera$1.01$0.97$0.55▼$1.19$12.93M0.81257,774 shs394,399 shsHYPDHyperion DeFi$3.11$3.47$2.49▼$16.35$47.15M2.49697,632 shs425,842 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMApollomics0.00%-5.96%+37.26%+33.74%+200.69%ATHEAlterity Therapeutics0.00%+9.50%+37.44%+51.16%+32.84%BFRIBiofrontera0.00%+4.02%+8.02%+2.02%+43.06%HYPDHyperion DeFi0.00%+2.81%+4.01%-5.76%-80.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLMApollomics 1.00SellN/AN/AATHEAlterity Therapeutics 2.40Hold$13.00142.54% UpsideBFRIBiofrontera 2.00HoldN/AN/AHYPDHyperion DeFi 2.00Hold$6.95123.47% UpsideCurrent Analyst Ratings BreakdownLatest BFRI, ATHE, HYPD, and APLM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026HYPDHyperion DeFi Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$4.00 ➝ $6.606/30/2026ATHEAlterity Therapeutics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.006/29/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/24/2026HYPDHyperion DeFi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/23/2026APLMApollomics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/17/2026ATHEAlterity Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/16/2026ATHEAlterity Therapeutics LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.006/8/2026HYPDHyperion DeFi Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.25 ➝ $7.306/4/2026APLMApollomics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/1/2026BFRIBiofrontera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/20/2026HYPDHyperion DeFi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLMApollomics$8.50M5.06N/AN/A($2.89) per share-6.77ATHEAlterity TherapeuticsN/AN/AN/AN/A$3.10 per shareN/ABFRIBiofrontera$41.71M0.31N/AN/A$0.90 per share1.12HYPDHyperion DeFi$810K58.21N/AN/A$4.73 per share0.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLMApollomics-$10.94MN/AN/AN/AN/AN/AN/AN/A9/24/2026 (Estimated)ATHEAlterity Therapeutics-$7.87MN/AN/AN/AN/AN/AN/AN/A8/28/2026 (Estimated)BFRIBiofrontera-$10.54M-$0.97N/A16.83N/A-25.66%-515.34%-53.91%8/12/2026 (Estimated)HYPDHyperion DeFi-$45.31M-$9.95N/A2.70N/AN/A-91.59%-73.08%N/ALatest BFRI, ATHE, HYPD, and APLM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026BFRIBiofrontera-$0.1150-$0.41-$0.2950-$0.41$10.25 million$10.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPLMApollomicsN/AN/AN/AN/AN/AATHEAlterity TherapeuticsN/AN/AN/AN/AN/ABFRIBiofronteraN/AN/AN/AN/AN/AHYPDHyperion DeFiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLMApollomicsN/A0.960.96ATHEAlterity TherapeuticsN/A21.97N/ABFRIBiofrontera0.781.201.09HYPDHyperion DeFi0.121.971.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLMApollomics19.13%ATHEAlterity Therapeutics2.14%BFRIBiofrontera10.08%HYPDHyperion DeFi25.84%Insider OwnershipCompanyInsider OwnershipAPLMApollomicsN/AATHEAlterity Therapeutics38.80%BFRIBiofrontera8.10%HYPDHyperion DeFi7.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLMApollomics452.20 millionN/ANot OptionableATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableBFRIBiofrontera7012.80 million11.77 millionNo DataHYPDHyperion DeFi4015.16 million14.02 millionNo DataBFRI, ATHE, HYPD, and APLM HeadlinesRecent News About These CompaniesHyperion DeFi Stockholders Maintain Governance and Board StabilityJuly 1, 2026 | tipranks.comHyperion Gains on Blockdaemon HookupJune 23, 2026 | baystreet.caHyperion DeFi Taps Blockdaemon to Expand Hyperliquid Staking InfrastructureJune 23, 2026 | finance.yahoo.comHyperion DeFi and Blockdaemon Partner to Expand Institutional Hyperliquid Staking InfrastructureJune 22, 2026 | globenewswire.comAnalysts Conflicted on These Healthcare Names: Aveanna Healthcare Holdings (AVAH), Kura Oncology (KURA) and Hyperion DeFi (HYPD)June 12, 2026 | theglobeandmail.comHyperion DeFi Reiterates Guidance on Sunset of USDH and Felix MarketsJune 8, 2026 | markets.businessinsider.comHyperion DeFi, Inc. Maintains 2026 Financial Guidance Despite Partnership Changes with Native Markets and Felix MarketsJune 8, 2026 | quiverquant.comQHyperion DeFi Reiterates Guidance on Sunset of USDH and Felix MarketsJune 8, 2026 | globenewswire.comHyperion DeFi to Reclaim 800,000 HYPE for New Yield StrategiesJune 7, 2026 | financefeeds.comFHyunsu Jung Acquires 7,000 Shares of Hyperion DeFi (NASDAQ:HYPD) StockJune 3, 2026 | insidertrades.comHyperion DeFi Inc HYPDMay 20, 2026 | morningstar.comMHyperion DeFi Signals Strong Momentum in EarningsMay 20, 2026 | tipranks.comHyperion DeFi Stock Short Interest Report | NASDAQ:HYPD | BenzingaMay 16, 2026 | benzinga.comHyperion DeFi, Inc. (NASDAQ:HYPD) Q1 2026 Earnings Call TranscriptMay 15, 2026 | insidermonkey.comHyperion DeFi Inc (HYPD) Q1 2026 Earnings Call Highlights: Strong Growth Amidst Token VolatilityMay 14, 2026 | finance.yahoo.comHyperion DeFi (HYPD) Q1 2026 Earnings TranscriptMay 14, 2026 | finance.yahoo.comHyperion DeFi Reports 1Q 2026 Financial Results with Record Net Income and Raises Guidance for Full Year 2026May 14, 2026 | globenewswire.comHyperion DeFi Announces Underwritten Common Stock OfferingMay 8, 2026 | theglobeandmail.comHyperion DeFi Announces Closing of Public Offering of Common StockMay 8, 2026 | globenewswire.comHyperion DeFi Announces Pricing of Public Offering of Common StockMay 6, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026Flying Under the Radar: Lockheed Martin's $2.8B Stealth SetupBy Jeffrey Neal Johnson | June 17, 2026Father's Day Investing: 3 Stocks Built for Long-Term ReturnsBy Chris Markoch | June 16, 2026Strategy’s Bitcoin Rally Has a Hidden EngineBy Jeffrey Neal Johnson | June 16, 2026Allstate’s Comeback Is Turning Into a Profit MachineBy Peter Frank | June 8, 2026BFRI, ATHE, HYPD, and APLM Company DescriptionsApollomics NASDAQ:APLM$19.56 0.00 (0.00%) Closing price 07/2/2026 03:59 PM EasternExtended Trading$18.83 -0.73 (-3.73%) As of 08:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.Alterity Therapeutics NASDAQ:ATHE$5.36 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$5.46 +0.10 (+1.88%) As of 08:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Biofrontera NASDAQ:BFRI$1.01 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$1.03 +0.02 (+2.48%) As of 08:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Hyperion DeFi NASDAQ:HYPD$3.11 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$3.10 -0.01 (-0.26%) As of 08:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
